Use access key #2 to skip to page content.
$34.52 1.16 (3.48%)
7/23/2008 4:00 PM

Acorda Therapeutics, Inc. (ACOR)

CAPS Rating:
*

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ACOR

Add Stock to Watchlist

What the Community Thinks

Total Members

134 Outperforms
101 Underperforms
 

All-Stars

28 Outperforms
50 Underperforms
 

Wall Street

5 Outperforms
2 Underperforms
 

Members bullish on ACOR are also bullish on:

Members bearish on ACOR are also bearish on:

Ticker Tags

Biotechnology (294), Small Cap (1922), Rule Breakers Universe (161)
Suggest a tag

Acorda Therapeutics, Inc. At A Glance

Current Price: $34.52
Last Trade Time: 7/23/2008 4:00 PM
Open: $0.00
Previous Close: $33.36
Daily Range: $33.27 - $34.79
52-Week Range: $15.80 - $34.24
Volume: 663,413
Market Cap: $1.09B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

ACOR VS S&P 500 (SPY)

ACOR 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for ACOR

More Headlines...

Top Bull Pitch

Recs

5

Acorda Therapeutics, Inc. (ACOR)

Avatar BoringIsNormal (43.94) Submitted: 3/18/08 3:37 PM

Once they get Phamberine XR approved by the FDA the stock will shine, if not... well it's pretty much the end, they can't stay afloat with zanflax especially with all the debt they are using for research into XR.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Acorda Therapeutics, Inc. (ACOR)

Avatar evillate (< 20) Submitted: 6/02/08 11:07 AM

Big jump is too big. I'll watch it come down

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 34 :   1 2 3 4 5 Next »

Recs

0

 (ACOR)

Avatar corepunch (52.61) Submitted: 7/07/08 11:20 PM : Underperform Start Price: $31.69 ACOR Score: -6.35

not gonna meet earnings

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACOR)

Avatar jetlith (53.79) Submitted: 7/03/08 10:40 PM : Underperform Start Price: $32.59 ACOR Score: -4.83

topped out

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACOR)

Avatar BustaCAPS (58.58) Submitted: 6/30/08 10:59 AM : Underperform Start Price: $33.55 ACOR Score: -3.14

Over priced.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACOR)

Avatar tixareforkids (< 20) Submitted: 6/28/08 1:09 PM : Underperform Start Price: $33.16 ACOR Score: -3.88

short until Fampridine-SR result are in early '09, then we'll see..

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (ACOR)

Avatar ScreenerStizBear (< 20) Submitted: 6/26/08 2:26 PM : Underperform Start Price: $31.31 ACOR Score: -10.88

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 34 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackZacks 90.45 06/04/08 Underperform 3M $30.15+14.49%-7.11%-21.60 Toggle the visibility of 60-Second Pitch and replies
TrackFortisBank 98.29 06/21/07 Outperform NS $17.87+93.17%-15.28%+108.46
TrackBofASec 96.35 06/19/07 Outperform NS $19.60+76.12%-15.88%+92.01
TrackDeutscheSec 89.63 04/12/07 Outperform NS $23.50+46.89%-11.33%+58.23
TrackMorganJos < 20 02/21/07 Underperform NS $23.40+47.52%-11.95%-59.47
TrackJimCramer 81.15 10/12/06 Underperform 3W $17.12+101.64%-6.24%-107.88
TrackPiperJaff 78.77 09/29/06 Outperform NS $9.73+254.78%-4.16%+258.94
TrackLazardCapit 80.77 09/26/06 Outperform NS $10.09+242.12%-3.23%+245.35

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners